5F-PB-22 (5F-QUPIC or quinolin-8-yl 1-pentyfluoro-1H-indole-3-8-carboxylate) is a designer drug which acts as a cannabinoid agonist.

[2] The structure of 5F-PB-22 appears to have been designed with an understanding of structure–activity relationships within the indole class of cannabinoids.

[5] In January 2014, 5F-PB-22 was designated as a Schedule I controlled substance in the United States after several deaths were associated with its use.

[6][7] In the United Kingdom, 5F-PB-22 is now classified and controlled as a Class B drug, following the November 2016 amendment to the Misuse of Drugs Act 1971.

Several other synthetic cannabinoids structurally related to JWH-018, like 5F-PB-22, were also classified in this amendment.